Mike Northend
@mikenorthend.bsky.social
Haematologist at UCLH - cellular therapies & lymphoma
📍London
📍London
www.thelancet.com/journals/lan...
Happy to share 15 year follow-up of our study of rituximab Vs watchful waiting for advanced stage, asymptomatic low tumour burden FL. Substantial delay in TTNT with early rituximab makes it an excellent option for patients seeking to defer/avoid chemotherapy. #lymsm
Happy to share 15 year follow-up of our study of rituximab Vs watchful waiting for advanced stage, asymptomatic low tumour burden FL. Substantial delay in TTNT with early rituximab makes it an excellent option for patients seeking to defer/avoid chemotherapy. #lymsm
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
These mature data with 15 years of follow-up confirm that early rituximab monotherapy
substantially delays the need for new treatment for patients with advanced stage,
asymptomatic low tumour burden f...
www.thelancet.com
April 28, 2025 at 11:07 PM
www.thelancet.com/journals/lan...
Happy to share 15 year follow-up of our study of rituximab Vs watchful waiting for advanced stage, asymptomatic low tumour burden FL. Substantial delay in TTNT with early rituximab makes it an excellent option for patients seeking to defer/avoid chemotherapy. #lymsm
Happy to share 15 year follow-up of our study of rituximab Vs watchful waiting for advanced stage, asymptomatic low tumour burden FL. Substantial delay in TTNT with early rituximab makes it an excellent option for patients seeking to defer/avoid chemotherapy. #lymsm